CL2022002259A1 - Anticuerpos anti-axl y composiciones - Google Patents

Anticuerpos anti-axl y composiciones

Info

Publication number
CL2022002259A1
CL2022002259A1 CL2022002259A CL2022002259A CL2022002259A1 CL 2022002259 A1 CL2022002259 A1 CL 2022002259A1 CL 2022002259 A CL2022002259 A CL 2022002259A CL 2022002259 A CL2022002259 A CL 2022002259A CL 2022002259 A1 CL2022002259 A1 CL 2022002259A1
Authority
CL
Chile
Prior art keywords
compositions
axl antibodies
axl
antibodies
diseases
Prior art date
Application number
CL2022002259A
Other languages
English (en)
Inventor
Gjetting Torben
Lindsted Trine
Willer Anton
Worsaae Anne
Maria Carlsen Melander Eva
Schou Jakobsen Janus
Westh Hansen Randi
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of CL2022002259A1 publication Critical patent/CL2022002259A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención se refiere a anticuerpos anti-AXL y métodos para usarlos en el tratamiento de enfermedades y afecciones relacionadas con la actividad de AXL, por ejemplo, cáncer
CL2022002259A 2020-02-28 2022-08-18 Anticuerpos anti-axl y composiciones CL2022002259A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062982852P 2020-02-28 2020-02-28

Publications (1)

Publication Number Publication Date
CL2022002259A1 true CL2022002259A1 (es) 2023-04-14

Family

ID=75426640

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002259A CL2022002259A1 (es) 2020-02-28 2022-08-18 Anticuerpos anti-axl y composiciones

Country Status (16)

Country Link
US (1) US11807688B2 (es)
EP (1) EP4110824A1 (es)
JP (1) JP2023515821A (es)
KR (1) KR20220148237A (es)
CN (1) CN115210263A (es)
AR (1) AR121441A1 (es)
AU (1) AU2021225490A1 (es)
BR (1) BR112022015977A2 (es)
CA (1) CA3170975A1 (es)
CL (1) CL2022002259A1 (es)
CO (1) CO2022012159A2 (es)
IL (1) IL295596A (es)
MX (1) MX2022010670A (es)
PE (1) PE20221783A1 (es)
TW (1) TW202146455A (es)
WO (1) WO2021171257A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
BRPI0820543A2 (pt) 2007-11-15 2015-06-16 Chugai Pharmaceutical Co Ltd Anticorpo monoclonal capaz de ligar a anexelekto, e uso do mesmo
RU2577986C2 (ru) 2010-06-18 2016-03-20 Дженентек, Инк. Антитела против axl и способы их применения
MX2017007941A (es) 2014-12-18 2018-01-30 Bergenbio Asa Anticuerpos antagonistas anti-axl.
JP6892431B2 (ja) * 2015-07-10 2021-06-23 ゲンマブ エー／エス 癌治療用のａｘｌ特異的抗体−薬物コンジュゲート
GB201610902D0 (en) * 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
EP3774904A1 (en) * 2018-04-10 2021-02-17 Genmab A/S Axl-specific antibodies for cancer treatment

Also Published As

Publication number Publication date
PE20221783A1 (es) 2022-11-16
TW202146455A (zh) 2021-12-16
WO2021171257A1 (en) 2021-09-02
MX2022010670A (es) 2022-09-23
AR121441A1 (es) 2022-06-08
CN115210263A (zh) 2022-10-18
JP2023515821A (ja) 2023-04-14
BR112022015977A2 (pt) 2022-10-11
CA3170975A1 (en) 2021-09-02
IL295596A (en) 2022-10-01
US20210269532A1 (en) 2021-09-02
EP4110824A1 (en) 2023-01-04
US11807688B2 (en) 2023-11-07
KR20220148237A (ko) 2022-11-04
CO2022012159A2 (es) 2022-10-31
AU2021225490A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
BR112019006876A2 (pt) anticorpos e composições anti-lag-3
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
MX2019012233A (es) Anticuerpos anti-sirpa.
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
ECSP17062716A (es) Heterociclos bicíclicos como inhibidores de fgfr4
NI201700001A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
ECSP17064695A (es) Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
PE20181365A1 (es) Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos
CL2021000088A1 (es) Anticuerpos anti-cd27 (divisional de solicitud 779-2019).
MX2019010848A (es) Composiciones y procedimientos para el tratamiento del cancer.
BR112017006464A2 (pt) bloqueio de cd73
BR112016029916A2 (pt) inibidores mnk e métodos correlatos
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
MX2022009596A (es) Anticuerpos anti-ror1 y composiciones.
BR112022003956A2 (pt) Anticorpos anti-cd73
UY30525A1 (es) Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos
CL2018001108A1 (es) Composiciones y métodos para transducción de tumores
BR112015023086A2 (pt) anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para produção de um anticorpo anti-cd25 ou fragmento ligante anti cd25, para prevenção de rejeição de órgãos transplantados e para tratamento de uma doença.
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
CO2020004984A2 (es) Proceso para preparar el benzotiofen-2-il boronato
BR112018068798A2 (pt) composições e métodos para tratamento de doenças parasíticas
CL2022002259A1 (es) Anticuerpos anti-axl y composiciones
CO2022019161A2 (es) Tubulisinas y conjugados de proteína-tubulisina